Kala Bio (KALA) Current Deferred Revenue (2022 - 2025)

Kala Bio (KALA) posted Current Deferred Revenue of $546000.0 for Q1 2025, down 14.29% sequentially from $637000.0 in Q4 2024.

Kala Bio (KALA) Current Deferred Revenue (2022 - 2025) Analysis & Trends

Kala Bio has reported Current Deferred Revenue for 4 years, with the latest figure at $546000.0 in Q1 2025.

Quarterly Current Deferred Revenue changed N/A year-over-year to $546000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $546000.0 (changed N/A YoY) and the FY2024 annual result came in at $637000.0, down 40.74% from the prior year.
Current Deferred Revenue slipped to $546000.0 in Q1 2025 per KALA's latest filing, from $637000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $4.2 million in Q4 2022 and troughed at $314000.0 in Q3 2024.
A 4-year average of $2.4 million and a median of $2.6 million in 2023 frame the typical range for Current Deferred Revenue.
The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue retreated 14.03% in 2023, then plunged 89.28% in 2024.
Over 4 years, Current Deferred Revenue stood at $4.2 million in 2022, then tumbled by 74.34% to $1.1 million in 2023, then slumped by 40.74% to $637000.0 in 2024, then decreased by 14.29% to $546000.0 in 2025.
According to Business Quant data, Current Deferred Revenue over the past three periods registered $546000.0, $637000.0, and $314000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Kala Bio	9.87 Mn	9.87 Mn	-

Download Data